Canagliflozin/metformin extended-release - Depomed/Janssen

Drug Profile

Canagliflozin/metformin extended-release - Depomed/Janssen

Alternative Names: CANA/MET XR FDC; Invokamet XR; Metformin extended-release/canagliflozin - Depomed/Janssen

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Depomed; Janssen Pharmaceutica
  • Class Antihyperglycaemics; Biguanides; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2017 Janssen Research and Development files sNDA to reduce the risk of major adverse cardiovascular events composed of cardiovascular death, myocardial infarction and stroke patients with Type 2 diabetes mellitus in USA
  • 16 May 2017 The US FDA issues the boxed warning for canagliflozin/metformin extended-release to include increased risk of leg and foot amputation
  • 01 Oct 2016 Janssen Research & Development completes a phase I bioequivalence trial in Healthy subjects in USA (NCT02846506)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top